| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2018-07-17 |
股东大会：
将于2018-08-22召开股东大会
会议内容 ▼▲
- 1.Approval of a reverse stock split at a ratio between one-for-five and one-for-twenty of our common stock, as determined by our board of directors, at any time before the earlier of August 22, 2019 and the next annual meeting of stockholders of the Company, if and as determined by our board of directors;
2.Approval of a proposal for the adjournment of the Special Meeting to permit the Company to solicit additional proxies, if there are insufficient proxies at the Special Meeting to approve the foregoing proposal.
|
| 2018-07-17 |
详情>>
股本变动：
变动后总股本3591.53万股
|
| 2018-04-02 |
详情>>
业绩披露：
2017年年报每股收益-2.11美元,归母净利润-2475.3万美元,同比去年增长39.08%
|
| 2017-12-19 |
股东大会：
将于2018-01-25召开股东大会
会议内容 ▼▲
- 1.Elect each of Daniel Kazado and Jeffrey Paley, M.D., nominees for Class I directors, as members of our Board of Directors;
2.Ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.Approve an amendment to our 2015 Equity Incentive Plan to increase the number of shares issuable under the plan from 750,000 to 3,500,000 and to eliminate the share limit on annual awards to any single participant (whether an employee, director or consultant) in any fiscal year;
4.Ratify the filing and effectiveness of the certificate of amendment to our certificate of incorporation filed with the Secretary of State of the State of Delaware on April 12, 2017 and the one for twenty reverse stock split of our common stock that was effected thereby and became effective on April 13, 2017;
5.Hold an advisory vote on our 2017 named executive officer compensation;
6.Hold an advisory vote on the frequency of the advisory vote on executive compensation;
7. Authorize the adjournment of the Annual Meeting if necessary or appropriate, including adjournment for the purpose of soliciting additional proxies if there are insufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals.
|
| 2017-11-14 |
详情>>
业绩披露：
2017年三季报(累计)每股收益-1.47美元,归母净利润-1474万美元,同比去年增长49.19%
|
| 2017-08-21 |
详情>>
业绩披露：
2017年中报每股收益-0.93美元,归母净利润-868.9万美元,同比去年增长25.75%
|
| 2017-06-14 |
详情>>
业绩披露：
2017年一季报每股收益-0.43美元,归母净利润-375.3万美元,同比去年增长37.64%
|
| 2017-05-17 |
详情>>
业绩披露：
2016年年报每股收益-9.58美元,归母净利润-4063.4万美元,同比去年增长-68.49%
|
| 2017-04-12 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2016-11-18 |
详情>>
业绩披露：
2016年三季报(累计)每股收益-0.46美元,归母净利润-2901万美元,同比去年增长-80.46%
|
| 2016-11-02 |
股东大会：
将于2016-12-15召开股东大会
会议内容 ▼▲
- 1. ratify the selection of BDO USA, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016;
2. approve an increase to the amount of shares authorized under the Company’s 2015 Equity Incentive Plan from 5,000,000 to 15,000,000;
3. re-elect each of Mr. Daniel G. Teper and Mr. John Neczesny, nominees for Class III directors, as members of our Board of Directors;
4. authorize an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a specific ratio, within a range of 1-for- 2 and 1-for-25, to be determined by our Board of Directors in its sole discretion and effected, if at all, on or before December 15, 2017.
|
| 2016-08-15 |
详情>>
业绩披露：
2016年中报每股收益-0.3美元,归母净利润-1170.2万美元,同比去年增长-41.88%
|
| 2016-05-16 |
详情>>
业绩披露：
2016年一季报每股收益-0.17美元,归母净利润-601.8万美元,同比去年增长-66.61%
|
| 2016-03-30 |
详情>>
业绩披露：
2015年年报每股收益-0.9美元,归母净利润-2411.6万美元,同比去年增长1.25%
|
| 2015-11-16 |
详情>>
业绩披露：
2015年三季报(累计)每股收益-0.63美元,归母净利润-1607.6万美元,同比去年增长7.56%
|
| 2015-11-13 |
股东大会：
将于2015-12-09召开股东大会
会议内容 ▼▲
- 1.ratify the selection of BDO USA, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2015;
2.approve the Immune Pharmaceuticals Inc. 2015 Equity Incentive Plan;
3.re-elect each of Mr. Cameron Durrant, M.D., and Mr. Elliot M. Maza, nominees for Class II directors, as members of our Board of Directors;
4.approve by an advisory vote the compensation of our named executive officers, as disclosed in this proxy statement.
|
| 2015-08-12 |
股东大会：
将于2015-08-31召开股东大会
会议内容 ▼▲
- 1.To approve the potential issuance of more than 19.99% of our outstanding common stock under our Series D Redeemable Convertible Preferred Stock, together with certain additional shares we issued pursuant to other transactions that are aggregated under the NASDAQ Listing Rules, in accordance with the stock purchase agreements between Immune Pharmaceuticals Inc. and Discover Growth Fund, dated July 28, 2015;
2.To transact such other business as may properly come before the special meeting or any adjournment or postponement thereof.
|
| 2014-11-26 |
详情>>
内部人交易：
Berdugo Gad等共交易5笔
|